Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Merck reported full-year 2025 results which were slightly ahead of expectations and provided initial 2026 guidance which was in line with already conservative expectations. Despite an expected...
— Glenn Fortin and Rui Cardoso
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Merck & Co., Inc.
No other institutional pitches found for this ticker yet.
More institutional theses from Brown Advisory
While Qualcomm's near-term outlook is impacted by temporary handset market weakness, its automotive and IoT segments show robust growth. The company's data...
Amdocs maintained near-perfect contract renewal rates, but its share price was negatively impacted by short-term revenue lumpiness and a CEO transition. The manager believes...
Union Pacific possesses a unique, expansive rail network with sole access to all gateways into Mexico. Its structurally robust...